Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic assay

A molecular and disease-based technology, applied in the parameter field of prognostic symptom analysis, which can solve problems such as irrelevant scope and lack of clear understanding.

Inactive Publication Date: 2004-12-29
THE UNIV OF SYDNEY
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A particularly potent marker for silent myocardial infarction was the identification of the MB isoform of creatine kinase (CK-MB), but this did not correlate with the range of other markers
[0009] There are many causes of AMI, but none of them are clearly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic assay
  • Diagnostic assay
  • Diagnostic assay

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0402] Early biochemical markers of cardiac disease or event

[0403] Myoglobin, CK-MB, cardiac troponin-T and cardiac troponin-I

[0404] For early markers, the priority is to implement detection as soon as possible in the short term, and markers should be released soon after ACS (including AMI). Even more ideally, early diagnosis of ACS (including AMI) would be with a Point-of-Care device, a small, hand-held device that can be used when a potential ACS (including AMI) patient presents In clinics including hospitals or clinics of general physicians.

[0405] Regarding early markers, myoglobin, total creatine kinase (CK) including creatine kinase CK-MB isoform, cardiac troponin-T (cTn-T) and cardiac troponin-I (cTn-1 ), each exhibits slightly different characteristics based on:

[0406] (1) Whether it specifically targets cardiac tissue;

[0407] (2) The time when the serum level reached its peak;

[0408] (3) The duration of the peak level;

[0409] (4) cli...

Embodiment 2

[0420] Effectiveness assessment of diagnostic equipment performance

[0421] The validity (E) of the diagnostic analysis can be obtained by the following formula:

[0422] E = TP TO × 100

[0423] Among them, TP is a true positive, TO is the total number of experiments, and TO is calculated as follows: TO=TP+FP+FN+TN, where FP is a false positive, FN is a false negative, TN is a true negative, and the value range of E: 0

Embodiment 3

[0425] Estimation of infarct size

[0426] Changes in biochemical markers were determined with autopsy and correlated with infarct size as a function of time. Clearly, the reliability of these algorithms is enhanced if they can be checked in multiple ways.

[0427] Infarct volume is a function of:

[0428] (1) The time span of release of biochemical markers

[0429] (2) Release rate of biochemical markers (f(t));

[0430] (3) The patient's body weight (Bw);

[0431] (4) The ratio of released biochemical markers to body weight (Kw);

[0432] (5) The removal ratio (Ed) of biochemical markers in circulation;

[0433] (6) The amount of markers released by the infarcted myocardium (Kr) divided by the total amount of biochemical markers released.

[0434] Accordingly, infarct size (Is) was determined using the following formula:

[0435] Is = ∫ 0 t ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates generally to a diagnostic device including a prognostic assay for parameters which are indicative of a condition or event associated with the systemic vasculature. More particularly, the present invention provides an assay to detect parameters associated with a vascular disease including cardiovascular, stroke, pulmonary, renovascular, cerebrovascular, thrombotic or generalized arterial or venous condition or event including acute coronary syndrome such as but not limited to acute myocardial infarction, heart failure, atheromoma or a thrombotic condition. The identification of these parameters or more particularly a pattern of parameters enables the diagnosis of a condition or event or the determination of the risk of development of a condition or event associated to the systemic vasculature. Still more particularly, the present invention is directed to a diagnostic device comprising a set of members wherein one or more of said members has o r have specific or generic binding partners in a biological sample from an animal including human subject wherein the pattern of binding of the members to the binding partners is indicative, predictive or otherwise associated with a likelihood of a condition or event within the systemic vasculature. The absence of detection of specific or generic binding partners is also of indicative o r predictive value.

Description

field of invention [0001] The present invention relates to a diagnostic device comprising parameters for prognostic symptom analysis indicative of conditions or events related to the systemic vasculature. More particularly, the present invention provides an analytical method for detecting parameters associated with vascular disease including: cardiovascular, stroke, pulmonary, renal vascular, cerebrovascular, thrombotic, or systemic arterial or venous conditions or events, also includes acute coronary syndromes such as but not limited to acute myocardial infarction, heart failure, atherosclerosis and thrombosis. Identification of these parameters, or even a pattern of them, aids in diagnosing, or determining the likelihood of, a condition or event associated with a systemic vasculature disorder or event. More particularly, the diagnostic device provided by the present invention comprises a set of components, one or more of which have specific or non-specific binding to biolog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/543G01N33/569G01N33/68G01N33/53G01N37/00G06F19/00
CPCG01N2800/324G01N33/6893Y02A90/10G01N33/53
Inventor R·I·克里斯托弗尔森C·G·多斯勒密迪奥斯D·S·赛勒玛伊尔
Owner THE UNIV OF SYDNEY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com